消化管疾患治療薬(一般用医薬品)の世界市場:胃食道逆流症(GERD)、便秘、下痢、吐気、鼓腸...市場調査レポートについてご紹介

【英文タイトル】Global Gastrointestinal OTC Drugs Market 2015-2019

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market overview
03.2 Product offerings

04.Market Research Methodology
04.1 Market research process
04.2 Research methodology

05.Introduction

06.Overview: OTC Drugs
06.1 Regulatory pathways for OTC approval
06.2 FDA OTC drug approval process
06.2.1 OTC NDA
06.2.2 OTC drug monograph
06.2.3 Gastrointestinal prescription to OTC switch

07.Epidemiology of Gastrointestinal Disorders

08.Market Landscape
08.1 Market overview
08.2 Market size and forecast
08.3 Top predictions
08.4 Five forces analysis

09.Market Segmentation by Therapeutic Class of Drug
09.1.1 Gastric acid reducers
09.1.2 Gastric acid neutralizers
09.1.3 Laxatives
09.1.4 Antidiarrheals
09.1.5 Antiemetics
09.1.6 Others

10.Market Segmentation by Indication
10.1.1 GERD
10.1.2 Constipation
10.1.3 Diarrhea
10.1.4 Nausea caused by motion sickness
10.1.5 Flatulence

11.Geographical Segmentation
11.1 Gastrointestinal OTC drugs market in Americas
11.1.1 Market size and forecast
11.2 Gastrointestinal OTC drugs market in EMEA
11.2.1 Market size and forecast
11.3 Gastrointestinal OTC drugs market in APAC
11.3.1 Market size and forecast

12.Buying Criteria

13.Market Growth Drivers

14.Drivers and their Impact

15.Market Challenges

16.Impact of Drivers and Challenges

17.Market Trends

18.Trends and their Impact

19.Vendor Landscape
19.1 Competitive scenario
19.1.1 Key news
19.1.2 Mergers and acquisitions
19.2 Market share analysis 2014
19.2.1 Bayer
19.2.2 GlaxoSmithKline
19.2.3 Johnson & Johnson
19.2.4 Perrigo
19.2.5 Pfizer
19.2.6 P&G
19.3 Other prominent vendors

20.Key Vendor Analysis
20.1 Bayer
20.1.1 Key facts
20.1.2 Business overview
20.1.3 Business segmentation by revenue 2014
20.1.4 Business segmentation by revenue 2013 and 2014
20.1.5 Geographical segmentation by revenue 2014
20.1.6 Business strategy
20.1.7 Recent developments
20.1.8 SWOT analysis
20.2 GlaxoSmithKline
20.2.1 Key facts
20.2.2 Business overview
20.2.3 Business segmentation by revenue 2014
20.2.4 Business segmentation by revenue 2013 and 2014
20.2.5 Geographical segmentation by revenue 2014
20.2.6 Business strategy
20.2.7 Recent developments
20.2.8 SWOT analysis
20.3 Johnson & Johnson
20.3.1 Key facts
20.3.2 Business overview
20.3.3 Business segmentation by revenue 2014
20.3.4 Business segmentation by revenue 2013 and 2014
20.3.5 Geographical segmentation by revenue 2014
20.3.6 Business strategy
20.3.7 Recent developments
20.3.8 SWOT analysis
20.4 Perrigo
20.4.1 Key facts
20.4.2 Business overview
20.4.3 Business segmentation by revenue 2014
20.4.4 Business segmentation by revenue 2013 and 2014
20.4.5 Geographical segmentation by revenue 2014
20.4.6 Business strategy
20.4.7 Recent developments
20.4.8 SWOT analysis
20.5 Pfizer
20.5.1 Key facts
20.5.2 Business overview
20.5.3 Business segmentation by revenue 2014
20.5.4 Business segmentation by revenue 2013 and 2014
20.5.5 Geographical segmentation by revenue 2014
20.5.6 Business strategy
20.5.7 Key developments
20.5.8 SWOT analysis
20.6 P&G
20.6.1 Key facts
20.6.2 Business overview
20.6.3 Business segmentation by revenue 2014
20.6.4 Business segmentation by revenue 2013 and 2014
20.6.5 Geographical segmentation by revenue 2014
20.6.6 Business strategy
20.6.7 Recent developments
20.6.8 SWOT analysis

21.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market research methodology
Exhibit 2: Comparison between prescription and OTC drugs
Exhibit 3: Advantages and disadvantages of OTC drugs
Exhibit 4: Ways to establish an OTC drug in different markets
Exhibit 5: Key regulatory bodies for OTC approval
Exhibit 6: FDA OTC drug approval process
Exhibit 7: Comparison of NDA versus OTC monograph process
Exhibit 8: Mechanisms to amend an OTC drug monograph
Exhibit 9: Drugs underwent Rx-to-OTC switch in US
Exhibit 10: Global gastrointestinal OTC drugs market 2014-2019 ($ million)
Exhibit 11: Top predictions in global gastrointestinal OTC drugs market
Exhibit 13: Global gastrointestinal OTC drugs market by therapeutic class of drug
Exhibit 14: Global gastrointestinal OTC drugs market by therapeutic class of drug 2014
Exhibit 15: Global gastrointestinal OTC drugs market by indication
Exhibit 16: Segmentation of global gastrointestinal OTC drugs market by geography 2014
Exhibit 17: Segmentation of global gastrointestinal OTC drugs market by geography 2019
Exhibit 18: Gastrointestinal OTC drugs market in Americas 2014-2019 ($ million)
Exhibit 19: Gastrointestinal OTC drugs market in EMEA 2014-2019 ($ million)
Exhibit 20: Gastrointestinal OTC drugs market in APAC 2014-2019 ($ million)
Exhibit 21: Key takeaways: Bayer
Exhibit 22: Key takeaways: GlaxoSmithKline
Exhibit 23: Key takeaways: Johnson & Johnson
Exhibit 24: Key takeaways: Perrigo
Exhibit 25: Product portfolio matrix of major vendors
Exhibit 26: Key takeaways: Pfizer
Exhibit 27: Key takeaways: P&G
Exhibit 28: Bayer: business segmentation by revenue 2014
Exhibit 29: Bayer: business segmentation by revenue 2013 and 2014 (US$ billion)
Exhibit 30: Bayer: geographical segmentation by revenue 2014
Exhibit 31: GlaxoSmithKline: business segmentation by revenue 2014
Exhibit 32: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 33: GlaxoSmithKline: geographical segmentation by revenue 2014
Exhibit 34: Johnson & Johnson: business segmentation by revenue 2014
Exhibit 35: Johnson & Johnson: business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 36: Johnson & Johnson: geographical segmentation by revenue 2014
Exhibit 37: Perrigo: business segmentation by revenue 2014
Exhibit 38: Perrigo: business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 39: Perrigo: geographical segmentation by revenue 2014
Exhibit 40: Pfizer: business segmentation by revenue 2014
Exhibit 41: Pfizer: business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 42: Pfizer: geographical segmentation by revenue 2014
Exhibit 43: P&G: business segmentation by revenue 2014
Exhibit 44: P&G: business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 45: P&G: geographical segmentation by revenue 2014


【レポート販売概要】

■ タイトル:消化管疾患治療薬(一般用医薬品)の世界市場:胃食道逆流症(GERD)、便秘、下痢、吐気、鼓腸
■ 英文:Global Gastrointestinal OTC Drugs Market 2015-2019
■ 発行日:2015年4月15日
■ 調査会社:Technavio
■ 商品コード:IRTNTR5810
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。